{"id":8643,"date":"2026-05-08T09:10:26","date_gmt":"2026-05-08T09:10:26","guid":{"rendered":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/"},"modified":"2026-05-08T09:10:26","modified_gmt":"2026-05-08T09:10:26","slug":"analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss","status":"publish","type":"post","link":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/","title":{"rendered":"Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2026\/05\/medicine_lab_office_data_pixabay_5.jpg\" alt=Analyzing Nestl\u00e9\u2019s GLP-1 Strategy:><br \/>\nAs the pharmaceutical landscape undergoes a seismic shift with the rise of GLP-1 receptor agonists like Ozempic and Wegovy, the global food industry is facing a transformative challenge. For investors and market analysts, <strong>Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution<\/strong> has become a critical exercise in understanding how legacy food giants can survive and thrive when consumers begin eating significantly fewer calories. While many competitors are bracing for a decline in volume, Nestl\u00e9 is positioning itself not as a victim of this trend, but as a primary &#8220;companion&#8221; to the GLP-1 user. This proactive approach is a cornerstone of <a href=\"https:\/\/quantstrategy.io\/blog\/the-future-of-food-stocks-navigating-the-glp-1-era-salty\">The Future of Food Stocks: Navigating the GLP-1 Era, Salty Snack Trends, and Sugar-Free Growth<\/a>, where the focus shifts from mass-market indulgence to specialized, nutrient-dense nutrition.<\/p>\n<h2 id=\"the-pivot-from-volume-to-nutrient-density\">The Pivot from Volume to Nutrient Density<\/h2>\n<p>The core of Nestl\u00e9\u2019s adaptation lies in recognizing that GLP-1 medications drastically reduce appetite and change food preferences. When patients consume 20% to 30% fewer calories, the nutritional value of every remaining bite becomes paramount. Nestl\u00e9 is pivoting its portfolio to address two specific risks associated with GLP-1 use: muscle mass loss (sarcopenia) and micronutrient deficiencies.<\/p>\n<p>Unlike companies heavily reliant on high-calorie, low-nutrition products, Nestl\u00e9 is leveraging its <strong>Nestl\u00e9 Health Science<\/strong> division to create products that support the specific physiological needs of weight-loss patients. This involves a strategic move toward &#8220;value density&#8221; rather than &#8220;volume growth.&#8221; Investors should note that while total tonnage sold might face headwinds, the margins on specialized medical nutrition often exceed those of traditional grocery items. This shift is essential for <a href=\"https:\/\/quantstrategy.io\/blog\/backtesting-consumer-staple-portfolios-during-healthcare\">Backtesting Consumer Staple Portfolios During Healthcare Disruptions<\/a>, as it demonstrates how specialized diversification acts as a hedge against changing consumer habits.<\/p>\n<h2 id=\"case-study-1-the-vital-pursuit-brand-launch\">Case Study 1: The &#8220;Vital Pursuit&#8221; Brand Launch<\/h2>\n<p>In May 2024, Nestl\u00e9 announced the launch of <strong>Vital Pursuit<\/strong>, a new line of frozen meals specifically designed for GLP-1 users. This represents a landmark example of how the company is executing its strategy. The product line focuses on several key attributes:<\/p>\n<ul>\n<li><strong>High Protein Content:<\/strong> To help preserve lean muscle mass during rapid weight loss.<\/li>\n<li><strong>Essential Nutrients:<\/strong> Including fiber, calcium, and iron to prevent common deficiencies.<\/li>\n<li><strong>Portion Control:<\/strong> Designed for the smaller appetites characteristic of GLP-1 patients.<\/li>\n<\/ul>\n<p>By branding these products specifically for weight-loss drug users, Nestl\u00e9 is capturing a niche that traditional &#8220;diet foods&#8221; often ignore. This targeted approach is a sophisticated evolution of <a href=\"https:\/\/quantstrategy.io\/blog\/theme-investing-how-glp-1-medications-are-reshaping-the\">Theme Investing: How GLP-1 Medications are Reshaping the Global Food Industry<\/a>, moving beyond general health claims to medical-adjacent consumer goods.<\/p>\n<h2 id=\"addressing-the-sugar-free-and-high-fiber-shift\">Addressing the Sugar-Free and High-Fiber Shift<\/h2>\n<p>As GLP-1 drugs reduce cravings for sweets and fats, Nestl\u00e9 is accelerating its efforts in sugar reduction and fiber enrichment. The company has long been a leader in using AI and proprietary technology to restructure sugar crystals, allowing for the same sweetness perception with significantly lower sugar content. This is a vital component of the broader trend toward <a href=\"https:\/\/quantstrategy.io\/blog\/the-rise-of-sugar-free-beverages-investing-in-the-health\">The Rise of Sugar-Free Beverages: Investing in the Health-Conscious Consumer Shift<\/a>.<\/p>\n<p>Furthermore, because GLP-1 medications slow gastric emptying, digestive health becomes a primary concern for patients. Nestl\u00e9\u2019s strategy includes integrating prebiotic fibers into everyday snacks and meals. This contrasts sharply with the outlook for some competitors; for more on that, see the <a href=\"https:\/\/quantstrategy.io\/blog\/salty-snack-stock-outlook-why-savory-cravings-still-drive\">Salty Snack Stock Outlook: Why Savory Cravings Still Drive Market Gains<\/a>. While savory snacks remain resilient due to different psychological triggers, Nestl\u00e9 is betting that the &#8220;functional&#8221; segment will see the most aggressive growth.<\/p>\n<h2 id=\"case-study-2-nestle-health-science-and-muscle-preservation\">Case Study 2: Nestl\u00e9 Health Science and Muscle Preservation<\/h2>\n<p>A second pillar of Nestl\u00e9\u2019s strategy involves its clinical nutrition portfolio. Brands like <strong>Boost<\/strong> and <strong>Garden of Life<\/strong> are being repositioned to assist GLP-1 patients in maintaining protein intake. During clinical trials, it was noted that a significant percentage of weight lost on GLP-1s could be muscle rather than fat. Nestl\u00e9 is developing specific protein powders and supplements that include amino acids like Leucine, which are critical for muscle protein synthesis.<\/p>\n<table border=\"1\" cellpadding=\"10\" cellspacing=\"0\" style=\"width: 100%; border-collapse: collapse;\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th>Strategic Pillar<\/th>\n<th>Primary Objective<\/th>\n<th>Key Brands Involved<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Companion Nutrition<\/strong><\/td>\n<td>Provide high-protein, nutrient-dense meals for GLP-1 users.<\/td>\n<td>Vital Pursuit, Lean Cuisine<\/td>\n<\/tr>\n<tr>\n<td><strong>Micronutrient Support<\/strong><\/td>\n<td>Address vitamins\/minerals lost due to reduced food intake.<\/td>\n<td>Nature\u2019s Bounty, Garden of Life<\/td>\n<\/tr>\n<tr>\n<td><strong>Sugar\/Fat Reduction<\/strong><\/td>\n<td>Reformulate treats to meet changing taste profiles.<\/td>\n<td>Nestl\u00e9 Cocoa Plan, Nescaf\u00e9<\/td>\n<\/tr>\n<tr>\n<td><strong>Digestive Wellness<\/strong><\/td>\n<td>Manage side effects like constipation via fiber.<\/td>\n<td>OptiFibre, Benefiber<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"actionable-insights-for-investors\">Actionable Insights for Investors<\/h2>\n<p>When analyzing Nestl\u00e9 through the lens of the GLP-1 revolution, investors should look beyond simple revenue growth. The key metrics are now <strong>R&#038;D efficiency<\/strong> and <strong>portfolio mix<\/strong>. Companies that can successfully use <a href=\"https:\/\/quantstrategy.io\/blog\/using-ai-models-to-predict-consumer-demand-for-sugar-free\">Using AI Models to Predict Consumer Demand for Sugar-Free Alternatives<\/a> will have a significant time-to-market advantage.<\/p>\n<p>For those managing volatility, understanding technical indicators is crucial. Monitoring <a href=\"https:\/\/quantstrategy.io\/blog\/chart-patterns-in-food-and-beverage-stocks-identifying\">Chart Patterns in Food &#038; Beverage Stocks: Identifying Breakouts in Volatile Markets<\/a> can help identify when the market has fully priced in the &#8220;GLP-1 threat&#8221; and begins to value the &#8220;GLP-1 opportunity.&#8221; Additionally, as sugar becomes a liability, monitoring <a href=\"https:\/\/quantstrategy.io\/blog\/commodity-futures-and-food-stocks-how-sugar-prices-impact\">Commodity Futures and Food Stocks: How Sugar Prices Impact Beverage Growth<\/a> can provide clues into Nestl\u00e9\u2019s input cost management during its transition.<\/p>\n<p>The psychology of these shifts is also fascinating. While GLP-1s suppress hunger, they do not entirely eliminate the <em>habit<\/em> of snacking. Nestl\u00e9 is banking on the fact that <a href=\"https:\/\/quantstrategy.io\/blog\/the-psychology-of-consumer-habits-why-salty-snacks-remain\">The Psychology of Consumer Habits: Why Salty Snacks Remain Resilient to Health Trends<\/a> will translate into a demand for &#8220;better-for-you&#8221; snacks that provide a sensory experience without the caloric baggage. For those looking to protect their positions during this transition, exploring <a href=\"https:\/\/quantstrategy.io\/blog\/hedging-food-stock-volatility-options-strategies-for-the\">Hedging Food Stock Volatility: Options Strategies for the Nestl\u00e9 GLP-1 Pivot<\/a> is highly recommended.<\/p>\n<h2 id=\"conclusion-the-future-of-the-nestle-portfolio\">Conclusion: The Future of the Nestl\u00e9 Portfolio<\/h2>\n<p>Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution reveals a company that is treating the rise of weight-loss drugs as a catalyst for innovation rather than a terminal threat. By focusing on nutrient density, muscle preservation, and digestive health, Nestl\u00e9 is carving out a &#8220;companion&#8221; category that could redefine the consumer staples sector. The transition will not be without its challenges\u2014particularly in its confectionery and high-calorie divisions\u2014but its massive investment in health science provides a safety net that most other food companies lack.<\/p>\n<p>Ultimately, Nestl\u00e9\u2019s success will depend on its ability to convince GLP-1 users that its products are essential medical companions rather than just optional snacks. This evolution is a vital part of the narrative found in <a href=\"https:\/\/quantstrategy.io\/blog\/the-future-of-food-stocks-navigating-the-glp-1-era-salty\">The Future of Food Stocks: Navigating the GLP-1 Era, Salty Snack Trends, and Sugar-Free Growth<\/a>, where the winners of the next decade will be those who adapt their portfolios to the biology of the modern consumer.<\/p>\n<h2 id=\"frequently-asked-questions\">Frequently Asked Questions<\/h2>\n<h3 id=\"how-specifically-does-nestles-glp-1-strategy-differ-from-its-traditional-diet-food-approach\">How specifically does Nestl\u00e9\u2019s GLP-1 strategy differ from its traditional diet-food approach?<\/h3>\n<p>Unlike traditional &#8220;low-calorie&#8221; diet foods that simply reduce fat or sugar, the GLP-1 strategy focuses on <strong>nutrient density<\/strong>. The goal is to provide high levels of protein, fiber, and essential micronutrients in small portions, specifically addressing the muscle loss and malnutrition risks associated with GLP-1 medications.<\/p>\n<h3 id=\"which-nestle-brands-are-most-at-risk-from-the-weight-loss-drug-trend\">Which Nestl\u00e9 brands are most at risk from the weight-loss drug trend?<\/h3>\n<p>The most vulnerable brands are those in the confectionery and high-sugar categories, such as KitKat or various ice cream brands. However, Nestl\u00e9 has already begun divestitures in North American mass-market confectionery to mitigate these risks and focus on premium or health-oriented segments.<\/p>\n<h3 id=\"is-nestles-health-science-division-a-significant-part-of-the-companys-revenue\">Is Nestl\u00e9\u2019s Health Science division a significant part of the company&#8217;s revenue?<\/h3>\n<p>Yes, Nestl\u00e9 Health Science has become a multi-billion dollar growth engine for the company. It represents a significant shift from a pure &#8220;food and beverage&#8221; company to a &#8220;nutrition, health, and wellness&#8221; company, providing a buffer against declines in traditional food consumption.<\/p>\n<h3 id=\"how-does-the-vital-pursuit-line-fit-into-the-broader-food-stock-market\">How does the &#8220;Vital Pursuit&#8221; line fit into the broader food stock market?<\/h3>\n<p>Vital Pursuit is a direct challenge to competitors who are slow to adapt to GLP-1 trends. It positions Nestl\u00e9 as a first-mover in &#8220;companion nutrition,&#8221; a theme explored deeply in our analysis of <a href=\"https:\/\/quantstrategy.io\/blog\/the-future-of-food-stocks-navigating-the-glp-1-era-salty\">The Future of Food Stocks: Navigating the GLP-1 Era<\/a>.<\/p>\n<h3 id=\"can-glp-1-drugs-actually-benefit-food-stock-investors-in-the-long-run\">Can GLP-1 drugs actually benefit food stock investors in the long run?<\/h3>\n<p>While GLP-1s may reduce total volume, they drive demand for high-margin, functional, and medical-grade food products. Investors who identify companies like Nestl\u00e9 that can capture this &#8220;premiumized nutrition&#8221; may find higher profitability despite lower overall calorie consumption.<\/p>\n<h3 id=\"what-role-does-ai-play-in-nestles-adaptation-to-the-glp-1-era\">What role does AI play in Nestl\u00e9\u2019s adaptation to the GLP-1 era?<\/h3>\n<p>Nestl\u00e9 uses AI to analyze massive datasets on consumer behavior and nutritional needs to predict which flavors and formats GLP-1 users will prefer. This technology allows them to reformulate products and launch new brands like Vital Pursuit much faster than traditional R&#038;D methods would allow.<\/p>\n","protected":false},"excerpt":{"rendered":"As the pharmaceutical landscape undergoes a seismic shift with the rise of GLP-1 receptor agonists like Ozempic and&hellip;\n","protected":false},"author":1,"featured_media":8642,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[66,67],"tags":[],"class_list":{"0":"post-8643","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-stocks-and-etfs","8":"category-theme-investing"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution - Learn Quant Trading | QuantStrategy.io<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution - Learn Quant Trading | QuantStrategy.io\" \/>\n<meta property=\"og:description\" content=\"As the pharmaceutical landscape undergoes a seismic shift with the rise of GLP-1 receptor agonists like Ozempic and&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/\" \/>\n<meta property=\"og:site_name\" content=\"Learn Quant Trading | QuantStrategy.io\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T09:10:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2026\/05\/medicine_lab_office_data_pixabay_5.jpg\" \/>\n<meta name=\"author\" content=\"QuantStrategy.io Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"QuantStrategy.io Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution - Learn Quant Trading | QuantStrategy.io","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/","og_locale":"en_US","og_type":"article","og_title":"Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution - Learn Quant Trading | QuantStrategy.io","og_description":"As the pharmaceutical landscape undergoes a seismic shift with the rise of GLP-1 receptor agonists like Ozempic and&hellip;","og_url":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/","og_site_name":"Learn Quant Trading | QuantStrategy.io","article_published_time":"2026-05-08T09:10:26+00:00","og_image":[{"url":"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2026\/05\/medicine_lab_office_data_pixabay_5.jpg"}],"author":"QuantStrategy.io Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"QuantStrategy.io Team","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/#article","isPartOf":{"@id":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/"},"author":{"name":"QuantStrategy.io Team","@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/person\/63aef420d635f0dc50f9ba974f6c95d1"},"headline":"Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution","datePublished":"2026-05-08T09:10:26+00:00","dateModified":"2026-05-08T09:10:26+00:00","mainEntityOfPage":{"@id":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/"},"wordCount":1427,"publisher":{"@id":"https:\/\/quantstrategy.io\/blog\/#organization"},"articleSection":["Stocks and ETFs","Theme Investing"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/","url":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/","name":"Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution - Learn Quant Trading | QuantStrategy.io","isPartOf":{"@id":"https:\/\/quantstrategy.io\/blog\/#website"},"datePublished":"2026-05-08T09:10:26+00:00","dateModified":"2026-05-08T09:10:26+00:00","breadcrumb":{"@id":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/quantstrategy.io\/blog\/analyzing-nestls-glp-1-strategy-adapting-to-the-weight-loss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/quantstrategy.io\/blog\/"},{"@type":"ListItem","position":2,"name":"Analyzing Nestl\u00e9\u2019s GLP-1 Strategy: Adapting to the Weight-Loss Drug Revolution"}]},{"@type":"WebSite","@id":"https:\/\/quantstrategy.io\/blog\/#website","url":"https:\/\/quantstrategy.io\/blog\/","name":"QuantStrategy.io - blog","description":"Blog","publisher":{"@id":"https:\/\/quantstrategy.io\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/quantstrategy.io\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/quantstrategy.io\/blog\/#organization","name":"QuantStrategy.io","url":"https:\/\/quantstrategy.io\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2023\/11\/qs_io_logo-80.png","contentUrl":"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2023\/11\/qs_io_logo-80.png","width":80,"height":80,"caption":"QuantStrategy.io"},"image":{"@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/person\/63aef420d635f0dc50f9ba974f6c95d1","name":"QuantStrategy.io Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/23922b0b6b220e6e9aca4c738eace72e744af8c32a4b3ee7ca8d7bbb8fc8d5b2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/23922b0b6b220e6e9aca4c738eace72e744af8c32a4b3ee7ca8d7bbb8fc8d5b2?s=96&d=mm&r=g","caption":"QuantStrategy.io Team"},"sameAs":["https:\/\/quantstrategy.io\/blog"],"url":"https:\/\/quantstrategy.io\/blog\/author\/razmik_davtyan\/"}]}},"_links":{"self":[{"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/posts\/8643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/comments?post=8643"}],"version-history":[{"count":0,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/posts\/8643\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/media\/8642"}],"wp:attachment":[{"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/media?parent=8643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/categories?post=8643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/tags?post=8643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}